• One-Stop CAR-T Therapy Development
  • Biomarker Identification & Selection
  • ScFv Generation
  • CAR Design & Construction
  • CAR-T Gene Packaging & Delivery
  • Replication-Competent Virus Testing
  • CAR Cell In Vitro Assay
  • CAR-T Preclinical In Vivo Assay
  • IND Development for CAR-T Cell Therapy
  • GMP Production for CAR-T Products
  • CAR Clinical Trial
  • One-Stop Canine CAR-T Therapy Development
  • One-Stop mRNA CAR-T Therapy Development
  • TRAC-CAR-T Cell Development
  • Modular CAR-T Cell Generation
  • One-Stop Silence™ CAR-T Cell Development
  • Vaccine Boosting CAR-T Cell Therapy
  • STAb-T Cell Therapy Development
  • CAR-T Therapy Development in the Non-Cancer Field
  • Anti-HIV CAR Cell Therapy Development
  • T Cell Activity Modulator Discovery
  • T Cell Programming
  • Virus Specific T Cell (VST) Development
  • Antibody-Coupled T Cell Receptor (ACTR) Development
  • Organoid-induced hPSC-original T Cell Differentiation
  • γδ T Cell Engineering
  • CAR-T CDMO
• One-Stop TCR-T Therapy Development
  • TCR Biomarker Identification & Selection
  • TCR Generation & Optimization
  • TCR Design & Construction
  • TCR Gene Packaging & Delivery
  • TCR In Vitro Assay
  • TCR-T Preclinical In Vivo Assay
  • TCR Clinical Application
  • TCR Analysis
  • TCR Tetramerization Construction
  • ScFv-TCR T Cell Therapy Development
  • AbTCR Development
  • Bispecific TCR Development
  • CER Development
• One-Stop CAR-MA Therapy Development
• One-Stop CAR-NK Therapy Development
  • One-Stop CAR-NKT Therapy Development
  • One-Stop UniCAR-NK Therapy Development
  • iPSC-derived CAR-NK Therapy Development
  • One-Stop TCR-NK Therapy Development
  • NK Cell Genetic Engineering
  • NK Cell Expansion
• One-Stop CAR-B Therapy Development
• One-Stop CAR-Monocyte Therapy Development
• One-Stop Cytokine Release Syndrome (CRS) Management
• TCR-Like Antibody Development
  • MHC/Peptide Complex Production
  • TCR-Like Antibody Discovery
  • TCR-Like Antibody Affinity Characterization
  • TCR-Like CAR Construction & Evaluation
• In Vivo Cell Engineering Development
  • In Vivo CAR-T Cell Engineering
  • In Vivo B Cell Engineering
  • In Vivo CAR-NK Cell Engineering
  • In Vivo CAR-M Cell Engineering
• One-Stop Allogeneic Cell Therapy Development
  • Allogeneic CAR-T Therapy Development
  • Allogeneic TCR-T Therapy Development
  • Allogeneic CAR-NK Therapy Development
  • Allogeneic CAR/TCR Cell Design & Engineering
  • Other Allogeneic Cell Therapy Development
• TCR/CAR/Antigen-Engineered Tregs Development
  • CAR-Treg Development
• Cancer Vaccine Development
  • Cancer Vaccine Discovery
  • Cancer Vaccine Engineering
  • Cancer Vaccine Analytical Characterization
  • Cancer Vaccine In Vivo Assessment
  • Cancer Vaccine GMP Manufacturing
  • Dendritic Cell Vaccine Development
• Immune Genotyping
  • HLA Typing
  • KIR Typing
  • HLA Testing
  • Dog DLA Genotyping
  • Guinea Pig GPLA Genotyping
  • Mouse H2 Genotyping
  • Rabbit RLA Genotyping
  • Rat RT1 Genotyping
  • Rhesus Macaque MHC Genotyping
• Other Services
  • Tumor-infiltrating Lymphocyte-based Antibody Discovery

Murine-Human Hybrid TCR Production Service

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Creative Biolabs provides services of both generation and validation of human TCR and murine-human hybrid TCR. Murine-human hybrid TCR is a promising strategy to improve cell surface TCR expression, TCR pairing and TCR/CD3ξ stability, which can enhance the anti-tumor activity of T cells.

Figure: Strategies addressing TCR pairing (Trends Mol Med. 2010)

The TCR (T-cell receptor)/CD3 complex is a structure to recognize antigens to active signals to lymphocytes. The association between TCR α, β chains and CD3γ/δ/ε/ζ is mediated by the transmembrane region residues that are located in the constant part of TCR chains. These charged residues interact with CD3ζ chain homodimer and CD3γ/ε-CD3δ/ε heterodimers noncovalently. There are reports that humanized murine TCRs might be less active than the native mouse receptor in human cells. However, TCRs with murine constant regions might have enhances tumor recognition and induce lymphocytes to secrete more IFN-γ, GM-CSF and other cytokines. The reason may be that the constant regions prefer to pair with themselves and decrease the mispairing with endogenous human TCR chains, increasing the stability of TCR/CD3ζ complex. Besides the functions in cytotoxic lymphocytes, the problem that the inherent CD4⁺ lymphocytes expressing class I MHC-restricted TCRs have low avidity can be overcome by using murine-human hybrid TCR.

For murine-human hybrid TCR generation, the human TCR which can recognize human tumor associated antigen is selected followed by the TCR-C domains (Cα and Cβ) replacement with the corresponding murine C domains. Then, a series of assays will be carried out to evaluate the expression and function of the resultant hybrid TCRs. Technically, we can use flow cytometry or other innovative strategies to test the specific antigen binding activity of TCR for assessing TCR pairing.

Our experienced scientists can design and select the appropriate and doable plan for TCR construct and optimization.

References:

1. Andreas Hombach, et al. T cell receptor gene therapy: strategies for optimizing transgenic TCR pairing. Trends Mol Med. 2010 Feb; 16(2):77-87.
2. Cyrille J. Cohen, et al. Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associatedwith improved pairing and TCR/CD3 stability. Cancer Res. 2006 Sep 1;66(17):8878-86.
3. Coen Govers, et al. T cell receptor gene therapy: strategies for optimizing transgenic TCR pairing. Trends Mol Med. 2010 Feb;16(2):77-87.

To discuss your demands or to request a proposal, please contact us by .